Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ariel Palenzuela-Diaz"'
Safety and Immunogenicity of Anti-SARS-CoV-2 Conjugate Vaccine SOBERANA 02: Phase IIb Clinical Trial
Autor:
Maria Eugenia-Toledo-Romani, Mayra García Carmenate, Leslyhana Verdecia-Sánchez, Suzel Pérez-Rodríguez, Meiby Rodriguez-González, Carmen Valenzuela-Silva, Beatriz Paredes-Moreno, Belinda Sánchez-Ramírez, Raul González-Mugica, Tays Hernández-García, Ivette Orosa-Vázquez, Marianniz Díaz-Hernández, María Teresa Pérez-Guevara, Juliet Enríquez-Puertas, Enrique Noa-Romero, Ariel Palenzuela-Diaz, Gerardo Baro-Roman, Ivis Mendoza-Hernández, Yaima Muñoz, Yanet Gómez-Maceo, Bertha Leysi Santos Vega, Sonsire Fernandez-Castillo, Yanet Climent-Ruiz, Laura Rodríguez-Noda, Darielys Santana-Mederos, Yanelda García-Vega, Guang Wu-Chen, Delaram Doroud, Alireza Biglari, Tammy Boggiano-Ayo, Yury Valdés-Balbín, Daniel G. Rivera, Dagmar García-Rivera, Vicente Verez-Bencomo, SOBERANA Research Group
Publikováno v:
SSRN Electronic Journal.
Autor:
Eduardo Ojito Magaz, Daniel G. Rivera, Ariel Palenzuela Diaz, Yanelda Garcia Vega, Leslihana Verdecia Sanchez, Tammy Boggiano Ayo, Meybis Rodriguez Gonzalez, Belinda Sánchez Ramírez, Anitza Fraga Quintero, Ivis Mendoza Hernandez, Yury Valdés Balbin, Franciscary Pi Estopinan, Guang-Wu Chen, Beatriz Perez Masson, Yanet Climent Ruiz, Sonsire Fernandez Castillo, Gretchen Bergado Báez, Otto Cruz Sui, Beatriz Paredes Moreno, Carmen Valenzuela Silva, Tays Hernandez Garcia, Gerardo Baro Roman, Dagmar García Rivera, Darielys Santana Mederos, Laura Rodriguez Noda, Vicente Verez Bencomo, Ubel Ramirez Gonzalez, Rocmira Perez Nicado, María Eugenia Toledo-Romaní, Raul Gonzalez Mugica, Majela Garcia Montero
BackgroundSOBERANA 02 is a COVID-19 conjugate vaccine candidate based on SARS-CoV-2 recombinant RBD conjugated to tetanus toxoid. SOBERANA Plus antigen is dimeric-RBD. Here we report safety, reactogenicity and immunogenicity from phase I and IIa clin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::585980601f45319168ec11e934bb3723
https://doi.org/10.1101/2021.11.14.21266309
https://doi.org/10.1101/2021.11.14.21266309
Autor:
María Eugenia Toledo-Romani, Mayra García-Carmenate, Leslyhana Verdecia-Sánchez, Suzel Pérez-Rodríguez, Meybis Rodriguez-González, Carmen Valenzuela-Silva, Beatriz Paredes-Moreno, Belinda Sanchez-Ramirez, Raúl González-Mugica, Tays Hernández-Garcia, Ivette Orosa-Vázquez, Marianniz Díaz-Hernández, María Teresa Pérez-Guevara, Juliet Enriquez-Puertas, Enrique Noa-Romero, Ariel Palenzuela-Diaz, Gerardo Baro-Roman, Ivis Mendoza-Hernández, Yaima Muñoz, Yanet Gómez-Maceo, Bertha Leysi Santos-Vega, Sonsire Fernandez-Castillo, Yanet Climent-Ruiz, Laura Rodríguez-Noda, Darielys Santana-Mederos, Yanelda García-Vega, Guang-Wu Chen, Delaram Doroud, Alireza Biglari, Tammy Boggiano-Ayo, Yury Valdés-Balbín, Daniel G. Rivera, Dagmar García-Rivera, Vicente Vérez-Bencomo, Mailin Cubas-Curbelo, Pedro Gabriel Rodríguez-Castillo, Yosmel Acevedo-Martínez, Solangel Estoque-Cabrera, José Alejandro Ávila-Cabreja, Ainadis Alfaro-Guzmán, Lilian Zulueta-Pérez, Niurka Tamara Espino-Rojas, Gloria Margarita Medinas-Santos, Ileana Luisa Sarda-Rodriguez, Mario Alejandro Acosta-Martinez, Radamet Reyes-Matienzo, José Manuel Coviella-Artime, Irania Morffi-Cinta, Marisel Martínez-Pérez, Rodrigo Valera-Fernández, Aniurka Garcés-Hechavarría, Dayle Martínez-Bedoya, Raine Garrido-Arteaga, Félix Cardoso-SanJorge, Ubel Ramírez-Gonzalez, Lauren Quintero-Moreno, Ivis Ontivero-Pino, Roselyn Martínez-Rivera, Berta Guillén-Obregón, Janet Lora-García, Maite Medina-Nápoles, Jennifer Espi-Ávila, Marcos Fontanies-Fernández, Yeney Regla Domínguez-Pentón, Gretchen Bergado-Baez, Franciscary Pi-Estopiñán, Eduardo Ojito-Magaz, Misladys Rodríguez, Otto Cruz-Sui, Majela García-Montero, Marta Dubed-Echevarría, Elena García-López, Evelyn Galano-Frutos, Alina Perez-Perez, Susana Morales-Ruano, Idalmis Brito-Pascual, Maité Amoroto, Amaylid Arteaga-García
Publikováno v:
Med. 3:760-773.e5
SOBERANA 02 has been evaluated in phase I and IIa studies comparing homologous versus heterologous schedule (this one, including SOBERANA Plus). Here, we report results of immunogenicity, safety, and reactogenicity of SOBERANA 02 in a two- or three-d
Autor:
Rinaldo Puga-Gómez, Yariset Ricardo-Delgado, Chaumey Rojas-Iriarte, Leyanis Céspedes-Henriquez, Misleidys Piedra-Bello, Dania Vega-Mendoza, Noelvia Pestana Pérez, Beatriz Paredes-Moreno, Meiby Rodríguez-González, Carmen Valenzuela-Silva, Belinda Sánchez-Ramírez, Laura Rodríguez-Noda, Rocmira Pérez-Nicado, Raul González-Mugica, Tays Hernández-García, Talía Fundora-Barrios, Martha Dubet Echevarría, Juliet María Enriquez-Puertas, Yenicet Infante-Hernández, Ariel Palenzuela-Díaz, Evelyn Gato-Orozco, Yanet Chappi-Estévez, Julio Cesar Francisco-Pérez, Miladi Suarez-Martinez, Ismavy C. Castillo-Quintana, Sonsire Fernandez-Castillo, Yanet Climent-Ruiz, Darielys Santana-Mederos, Yanelda García-Vega, María Eugenia Toledo-Romani, Delaram Doroud, Alireza Biglari, Yury Valdés-Balbín, Dagmar García-Rivera, Vicente Vérez-Bencomo, María Elena Mesa-Herrera, Yarmila García-Cristiá, Leonor Verdecia-Sánchez, Rafael del Valle Rodríguez, Yudalvies Oquendo-de la Cruz, Daysi Álvarez-Montalvo, Randy Grillo-Fortún, Liset López-González, Omaida Fonte Galindo, Yeseni Reyes-González, Ana Beatriz González-Álvarez, Linet Gorrita-Mora, Rodrigo Valera-Fernández, Ivis Ontivero-Pino, Marisel Martínez-Pérez, Esperanza Caballero-Gonzalez, Aniurka Garcés-Hechavarría, Dayle Martínez-Bedoya, Maite Medina-Nápoles, Yeney Regla Domínguez-Pentón, Yadira Cazañas-Quintana, Thais Fundora Barrios, Diana R. Hernández Fernández, Gretchen Bergado-Báez, Ivette Orosa-Vazquez, Franciscary Pi-Estopiñan, Marianniz Díaz-Hernández, Otto Cruz-Sui, Enrique Noa-Romero, Arilia García-López, Sandra Rivadereira Muro, Gerardo Baro-Roman
Publikováno v:
International Journal of Infectious Diseases, Vol 126, Iss , Pp 164-173 (2023)
Objectives: To evaluate a heterologous vaccination scheme in children 3-18 years old (y/o) combining two SARS-CoV-2r- receptor binding domain (RBD)protein vaccines. Methods: A phase I/II open-label, adaptive, and multicenter trial evaluated the safet
Externí odkaz:
https://doaj.org/article/88ee0659b0bf4cf3888a8d4fcd8fc08e
Autor:
Francisco Hernández-Bernal, Maria C. Ricardo-Cobas, Yenima Martín-Bauta, Zadis Navarro-Rodríguez, Marjoris Piñera-Martínez, Joel Quintana-Guerra, Karen Urrutia-Pérez, Klaudia Urrutia-Pérez, Cristina O. Chávez-Chong, Jorge L. Azor-Hernández, José L. Rodríguez-Reinoso, Leonardo Lobaina-Lambert, Elizabeth Colina-Ávila, Jacqueline Bizet-Almeida, Jeniffer Rodríguez-Nuviola, Sergio del Valle-Piñera, Mayara Ramírez-Domínguez, Elisangela Tablada-Ferreiro, Marel Alonso-Valdés, Gilda Lemos-Pérez, Gerardo E. Guillén-Nieto, Ariel Palenzuela-Díaz, Enrique Noa-Romero, Miladys Limonta-Fernández, Juan M. Fernández-Ávila, Nabil A. Ali-Mros, Lianne del Toro-Lahera, Rossana Remedios-Reyes, Marta Ayala-Ávila, Verena L. Muzio-González
Publikováno v:
EClinicalMedicine, Vol 46, Iss , Pp 101383- (2022)
Summary: Background: Multiple vaccine candidates against COVID-19 are currently being evaluated. We evaluate the safety and immunogenicity protein of a novel SARS-CoV-2 virus receptor-binding domain (RBD) vaccine. Methods: A phase 1-2, randomised, do
Externí odkaz:
https://doaj.org/article/701e99cfcb8c4480864eb76aad6725f5